Table 1 Baseline Demographics
Etoricoxib 60 mg | Etoricoxib 90 mg | Naproxen 1000 mg | Total | |
|---|---|---|---|---|
N = 702 | N = 156 | N = 157 | N = 1015 | |
n (%) | n (%) | n (%) | n (%) | |
Gender | ||||
Female | 209 (29.8) | 45 (28.8) | 41 (26.1) | 295 (29.1) |
Male | 493 (70.2) | 111 (71.2) | 116 (73.9) | 720 (70.9) |
Age (Years) | ||||
Mean (SD) | 45.4 (12.4) | 45.2 (11.3) | 44.5 (12.3) | 45.2 (12.2) |
Range | 19–82 | 19–82 | 21–75 | 19–82 |
Race | ||||
White | 589 (83.9) | 132 (84.6) | 138 (87.9) | 859 (84.6) |
Asian | 88 (12.5) | 17 (10.9) | 16 (10.2) | 121 (11.9) |
Multi-racial | 18 (2.6) | 5 (3.2) | 3 (1.9) | 26 (2.6) |
Black | 4 (0.6) | 2 (1.3) | 0 (0.0) | 6 (0.6) |
Other | 3 (0.4) | 0 (0.0) | 0 (0.0) | 3 (0.3) |
Chronic Peripheral Arthritis | 213 (30.3) | 44 (28.2) | 45 (28.7) | 302 (29.8) |
Radiographic Assessment (bilateral grade 4) a | 177 (25.2) | 38 (24.4) | 29 (18.5) | 244 (24.0) |
BASDAI >4 at Screening n/N (%) b | 314/624 (50.3) | 67/140 (47.9) | 76/141 (53.9) | 457/905 (50.5) |
Mean (SD) Baseline Spinal Pain Intensity (0–100 mm VAS) | 76.7 (14.2) | 76 (15.2) | 77.0 (14.0) | 76.8 (14.3) |